唯思派 唯思派
登录
  • 文献互助
  • 期刊检索
  • 开放文档
  • 文章资讯

全部| 求助中| 待确认 按时间排序|按积分排序

Macrocyclization of disubstituted arenes through a rhodium-catalyzed C–H alkenylation/annulation cascade

用户E7Ew3y8FhjMU 11天前 10 已关闭

Understanding Community Dynamics in Online Social Networks: A multidisciplinary review

用户KSHIDhBxbMNo 11天前 10 已完结

Development of multiple W/O/W emulsions as dermal carrier system for oligonucleotides: Effect of additives on emulsion stability

科研废材 11天前 10 已完结

Anal Cancer Risk Rises With Age and Time Among Cervical Cancer Survivors

乔垣结衣 11天前 10 已完结

Regulated cell death: signaling and mechanisms

用户VQyTvhKOPCT8 11天前 10 已完结

131I-间位碘代苄胍治疗恶性嗜铬细胞瘤/副神经节瘤的临床疗效分析

用户hmVaEh6oq4ys 11天前 10 已完结

Apoptosis in neurodegenerative disorders.

用户VQyTvhKOPCT8 11天前 10 已完结

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.

用户VQyTvhKOPCT8 11天前 10 已完结

Nature Reviews Molecular Cell Biology

用户VQyTvhKOPCT8 11天前 10 已关闭

High-Dose Aumolertinib for Untreated EGFR-Variant Non–Small Cell Lung Cancer With Brain Metastases

用户GDCFefnIuyG8 11天前 10 已完结
首页 上页 56 57 58 59 60 61 62 下页
用户头像

wispass

唯思派

唯思派微信公众号

唯思派微信公众号

高分求助
  • Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China

    503小时前

  • {Appendices}[Appendix I](Appendix I A. General Reagents) Macrogol 4000 - british pharmacopoeia[1668821579.875838.html]

    5010小时前

  • A meta-analysis of albuminuria as a surrogate endpoint for kidney failure

    1013分钟前

  • Phase II, Single-Center, Prospective Study of Intrathecal Thiotepa for the Prophylaxis of Secondary Central Nervous System Involvement in Highly Aggressive …

    103小时前

  • 9ALPHA-FLUORO-16ALPHA-METHYL-11BETA-17ALPHA, 21-TRIHYDROXY-1, 4-PREGNADIENE-3, 20-DIONE (DEXAMETHASONE).

    105小时前

  • Comparison of seven different enzymatic methods for serum glycated albumin in pregnant women: a multicenter study

    107小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com